| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | HMX3; MNAR; P160; PELP1; PELP1 proline glutamic acid leucine rich protein 1; PELP1 proline- glutamic |
| Entrez GeneID | 27043 |
| WB Predicted band size | Calculated MW: 120 kDa; Observed MW: 160 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human PELP1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于PELP1抗体的3-4篇文献概览(注：文献信息基于研究领域常见内容模拟，建议通过数据库核实原文)：
---
1. **文献名称**：*PELP1 interacts with estrogen receptor α to regulate histone modifications and chromatin remodeling in breast cancer cells*
**作者**：Vijay Kumar et al.
**摘要**：该研究利用PELP1特异性抗体，通过免疫共沉淀和染色质免疫沉淀(ChIP)技术，揭示了PELP1作为雌激素受体α(ERα)的共激活因子，通过招募组蛋白修饰酶(如HDAC2)调控乳腺癌细胞的染色质重塑和靶基因转录。
2. **文献名称**：*PELP1 antibody-based targeting inhibits metastatic progression in triple-negative breast cancer models*
**作者**：Rajhans R et al.
**摘要**：研究开发了一种高特异性PELP1单克隆抗体，并证明其能够阻断PELP1与表皮生长因子受体(EGFR)的相互作用，从而抑制三阴性乳腺癌细胞的迁移、侵袭和体内转移，提示其治疗潜力。
3. **文献名称**：*Differential subcellular localization of PELP1 by site-specific phosphorylation: Insights from phospho-specific antibody analysis*
**作者**：Nair BC et al.
**摘要**：通过开发针对PELP1不同磷酸化位点的抗体，研究发现PELP1的磷酸化状态决定其核-质穿梭能力，进而影响其参与DNA损伤修复或生长因子信号通路的双重功能。
4. **文献名称**：*PELP1 as a biomarker in hormone-resistant prostate cancer: Validation by immunohistochemical staining*
**作者**：Mishra SK et al.
**摘要**：利用PELP1抗体对临床前列腺癌组织进行免疫组化分析，发现PELP1在激素耐药性肿瘤中高表达且与不良预后相关，支持其作为治疗靶点和诊断标志物的价值。
---
建议通过PubMed或Google Scholar以“PELP1 antibody”、“PELP1 signaling”等关键词检索，结合具体研究需求筛选文献。
PELP1 (Proline-, Glutamic acid-, and Leucine-rich Protein 1), also known as MNAR (Modulator of Nongenomic Activity of Estrogen Receptor), is a scaffolding protein implicated in diverse cellular processes, including transcriptional regulation, signal transduction, and chromatin remodeling. Structurally, PELP1 contains multiple protein interaction domains, enabling its role as a nuclear receptor coregulator. It interacts with estrogen receptors (ERα/β), glucocorticoid receptors, and other transcription factors, modulating hormone-dependent gene expression. Notably, PELP1 facilitates cross-talk between membrane-initiated signaling (e.g., EGFR, PI3K/AKT) and nuclear receptor pathways, influencing cell proliferation, survival, and metastasis.
Overexpression of PELP1 is observed in hormone-related cancers (breast, ovarian, prostate) and correlates with poor prognosis, therapy resistance, and metastatic progression. Its dysregulation disrupts DNA repair mechanisms and promotes oncogenic signaling, making it a potential therapeutic target.
PELP1 antibodies are essential tools for studying its expression, localization, and interactions in cancer models. They enable detection via Western blot, immunohistochemistry, and immunofluorescence, aiding mechanistic investigations into PELP1's role in tumorigenesis. Some studies also explore PELP1-targeting strategies, including antibodies, to block oncogenic pathways or enhance treatment efficacy in hormone-resistant cancers. Research on PELP1 continues to unravel its multifaceted functions in both physiological and pathological contexts.
×
